A Detailed Analysis of the Functional Electrical Stimulation Market Based on Technological Advancements Enhancing Device Efficacy and Patient Outcomes
Report ID: PMRREP33943
Number of Pages: 215
Format: PPT*, PDF, EXCEL
Industry: Healthcare
Published Date: January-2024
The global functional electrical stimulation market is forecast to expand at a CAGR of 4.7% and thereby increase from a value of US$615.4 Mn in 2023, to US$848.8 Mn by the end of 2030.
|
Attributes |
Key Insights |
|
Functional Electrical Stimulation Market Size (2023E) |
US$615.4 Million |
|
Projected Market Value (2030F) |
US$848.8 Million |
|
Global Market Growth Rate (CAGR 2023 to 2030) |
4.7% |
|
Historical Market Growth Rate (CAGR 2018 to 2022) |
4.1% |
Report Sample is Available
In-depth report coverage is now just a few seconds away
Get Report Sample
Functional electrical stimulation (FES) represents an advanced technology utilizing low-energy electrical pulses to induce artificial body movements in individuals facing partial or complete paralysis. Initially considered as an assistive device, functional electrical stimulation has evolved into a highly therapeutic technique through extensive research and clinical trials. Presently, clinicians widely employ this method to assist patients recovering from paralysis, aiding them in regaining movement capabilities. Two primary causes of paralysis are stroke and spinal cord injury
The market's growth is driven by the escalating prevalence of musculoskeletal and central nervous system diseases, primary contributors to paralysis. According to a World Health Organization (WHO) report, there are annually 0.25 to 0.5 million new cases of spinal cord injuries, while 1.71 billion individuals suffer from musculoskeletal conditions, including 568 million with lower back-related issues. Furthermore, the increased integration of advanced technology in the healthcare sector is anticipated to propel market expansion.
Make This Report Your Own
Take Advantage of Intelligence Tailored to your Business Objective
Get a Customized VersionRising CNS Disorders
The anticipated growth of the global functional electrical stimulation market is expected to be fuelled by the increasing prevalence of central nervous system (CNS) disorders affecting the functions of the spinal cord or brain structure. In numerous CNS cases, patients often experience partial or complete paralysis, particularly when the spinal cord is significantly damaged. Causes of CNS disorders vary, encompassing factors such as trauma, degeneration, CNS tumors, stroke, autoimmune diseases, structural defects, and others. Additionally, the rising incidence of other musculoskeletal disorders (MSD) is poised to contribute to the overall market expansion. MSD encompasses injuries related to nerves, muscles, joints, tendons, spinal discs, and cartilage, with arthritis, back pain, and trauma being the most prevalent forms. If left untreated, these disorders may result in the loss of natural mobility, thereby driving the demand for functional electrical stimulation.
According to the National Center for Posttraumatic Stress Disorder (PTSD), 6 out of 10 men, and 5 out of every 10 women suffer from some form of trauma once in their lifetime, with severe trauma potentially causing long-lasting disruptions in brain function and subsequent loss of movement in specific body parts. The increasing endorsement of FES as a part of treatment plans by medical professionals is notable, given the positive outcomes reported by many patients undergoing FES treatments.
Risks Associated With FES
Given that FES involves the application of a low-voltage electric current, the integral component of this treatment is the use of electrodes positioned on the skin to facilitate the controlled flow of electric current. While this non-invasive procedure is generally safe under the supervision of experienced professionals, it is essential to acknowledge potential risks associated with the placement of electrodes beneath the skin or in deep tissue. These risks include the possibility of infection at the electrode site, wire breakage, and the development of scar tissue. Notably, externally placed electrodes have not been reported to exhibit any adverse effects. Businesses in the healthcare sector must be aware of and manage these considerations when implementing FES treatments.
High Cost of FES Treatment
The cost of FES systems typically spans a range of USD 4000 to USD 14000. This results in a comparatively elevated final treatment cost, particularly in developing nations characterized by lower-income demographics. The overall medical treatment expenses are contingent upon the specific device utilized and the duration of the treatment, posing a hindrance to widespread adoption. The considerable disparity in treatment costs may impede the global market's growth trajectory unless concerted efforts within the healthcare sector are undertaken to standardize treatment expenses, fostering greater accessibility for the general population.
Growing Research in FES
FES has a history dating back to the 1960s, and over the years, continuous research has been conducted to refine and enhance the FES process, recognizing its considerable potential. In the current landscape, both private enterprises and government institutions are actively investing in the field of FES, aiming to broaden its applications and make it more accessible to low-income demographics. This strategic focus on affordability and expanded accessibility is expected to present promising avenues for substantial growth in the global functional electrical stimulation market. The alignment of these factors underscores a compelling business opportunity in the FES sector for those seeking to capitalize on its expanding market presence.
Which is the Spearheading Product Type Segment?
Wired Functional Electrical Stimulation Leads on Account of Reliability, Ease of Integration, and Popularity in Therapeutic Scenarios
The segment of wired functional electrical stimulation commands a significant share in sales, primarily due to its established track record, reliability, and seamless integration with existing medical systems. This category is particularly prevalent in therapeutic scenarios demanding precise control and consistent performance. Healthcare professionals favor wired FES devices for their proven technology, facilitating targeted muscle stimulation and rehabilitation. Recognized as cost-effective for extended usage, these devices emerge as the preferred choice for universities. The widespread adoption of wired FES devices can be attributed to their familiarity and seamless integration into treatment protocols, consolidating their dominant position in functional electrical stimulation sales.
Which Area of Application is the Largest Revenue Contributor?
Neurological Disorders to be the Major Area of Application as Prevalence of Learning Disabilities, Epilepsy, Autism, and Cerebral Palsy Rises
Neurological disorders contribute significantly to the global market revenue, driven by the escalating prevalence of conditions such as learning disabilities, epilepsy, autism, and cerebral palsy. According to the Centers for Disease Control and Prevention (CDC) in the USA, the diagnosed cases of epilepsy exceeded 3.4 million in the year 2015. This underscores the substantial market opportunity within the neurological disorders segment, emphasizing the need for strategic considerations and investments in this area for business growth.
Which are the Primary End User Segment?
Hospitals to Dominate Sales Owing to Comprehensive Care Environment, and a Diverse Patient Base
The demand for functional electrical stimulation is particularly pronounced in the hospital segment, driven by the comprehensive care environment and diverse patient base it offers. Hospitals serve as central hubs for various medical specializations, ensuring accessibility to functional electrical stimulation for patients with diverse needs. The controlled setting of hospitals facilitates precise administration and supervision of FES, crucial for ensuring the safety and effectiveness of the treatment. Medical personnel in hospitals are well-equipped to integrate functional electrical stimulation into comprehensive patient care plans, thereby enhancing rehabilitation outcomes.
Increasing Patient Number with Chronic Pain to Fuel Leadership of North America
North America is poised to dominate the global functional electrical stimulation market, primarily fueled by a rising population grappling with conditions such as stroke, paralytic attacks, cerebral palsy, and various musculoskeletal disorders. The region's elevated prevalence of stroke cases is notably linked to a high obesity index attributed to unhealthy lifestyles and poor dietary habits. Furthermore, the regional market is expected to experience an upswing due to an increasing number of patients dealing with chronic pain. According to the Centers for Disease Control and Prevention (CDC), more than 20.4% of the population received a diagnosis of chronic pain in 2020. This substantial prevalence of medical conditions necessitating functional electrical stimulation treatments is projected to drive market growth in North America.
Increasing Government Spending on Healthcare to Benefit Asia Pacific
The anticipated surge in government spending on healthcare is projected to drive sales in the coming years. Additionally, the prevalence of musculoskeletal disorders in the region significantly influences the functional electrical stimulation market. Notably, Poland and Hungary stand out in Europe with the highest prevalence of musculoskeletal disorders, recording 6,737 and 6,697 cases per 100,000 population, respectively.
The functional electrical stimulation market is anticipated to undergo substantial expansion and change. Functional electrical stimulation manufacturers should develop compelling instructional materials that comprehensively outline the benefits, foundations, and applications of their FES technology. These materials should proactively address common queries and concerns that potential clients may have about FES. This strategic approach aims to establish the company's reputation as an authoritative and reliable source of information within the industry. Collaboration with medical professionals, physical therapists, and academic institutions is crucial for obtaining endorsements and recommendations for FES products. The support and commendation of healthcare professionals can significantly influence purchasing decisions in the healthcare sector. Additionally, manufacturers should offer training sessions to equip these professionals with the knowledge and skills needed to confidently recommend and utilize their FES products.
Supply-side Dynamics
Several factors, including the Rising musculoskeletal disorders and the increasing importance of pain management therapies in different areas of medicine, all contribute to the dynamic and rapid expansion of the global Functional Electrical Stimulation market. Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi S.A., and GlaxoSmithKline plc are market leaders in the manufacturing sector. The countries of Germany, Japan, China, France, and the United States are significant producers of various goods. The expansion of the market in Germany is being propelled by the growing government investments in the healthcare sector, the escalating utilization of spinal cord stimulation devices in home healthcare settings, and the increasing embrace of advanced medical device technologies by healthcare providers.
Several corporations are allocating resources toward expanding their capacity to satisfy the increasing need for innovative healthcare solutions and services. It is anticipated that these expansions will substantially alter the dynamics of the market, resulting in heightened competition, reduced prices, and an influx of innovative products. It is anticipated that expanding capacity will exert a substantial influence on market dynamics, resulting in heightened competition, reduced prices, and an increased availability of innovative products.
Prominent organizations, including Abbott Laboratories, Teva Pharmaceutical Industries Ltd., and Mylan N.V., are at the vanguard of this sector, providing inventive solutions by capitalizing on their technological prowess and developing and bringing fresh ideas and solutions to the market.
Established medical device companies are channeling investments into the research and development of Functional Electrical Stimulation (FES), leading to the creation of new products with improved functionality and enhanced user experience. Prominent functional electrical stimulation manufacturers are making substantial investments and collaborating with other entities to introduce new products, aiming to fortify their global market positions. Furthermore, to contend with the increasing market that is primarily motivated by concerns regarding safety and well-being, they must distinguish their products through innovative features, advanced technologies, and robust safety measures.
To distinguish themselves in this highly competitive market, these businesses strive to differentiate their products. They achieve this by providing advanced technological features, superior efficacy, and innovative solutions, addressing the specific needs of patients and healthcare professionals.
New Product Launch
In March 2019, a US-based company Innovative Neurological Devices, situated in Indiana, declared that the Cervelli Cranial Electrotherapy Stimulator had received FDA approval for treating insomnia, depression, and anxiety. The product has recently been recognized as an award-winning non-drug treatment for these disorders.
Market Impact: This development represents substantial progress in non-pharmacological therapy options for these disorders and may lead to a wider use of FES technologies for the treatment of neurological and psychiatric problems. The approval raises the credibility of FES-based treatments, which encourages more healthcare providers and patients to accept them.
(Source: NS Medical Devices)
In October 2020, the g.Estim FES, developed by g.tec Medical Engineering GmbH, received approval from the US Food and Drug Administration. This neuromuscular electrical stimulator is intended for use under strict supervision and serves as an adjunctive therapy for various medical conditions and diseases
Market Impact: This regulatory approval demonstrates the product's compliance with safety and aeffectiveness requirements, giving patients and healthcare providers confidence. g.Estim FES expands the use of FES technologies in treating a range of health issues by serving as an adjuvant therapy for several conditions and diseases.
|
Attribute |
Details |
|
Forecast Period |
2023 to 2030 |
|
Historical Data Available for |
2018 to 2022 |
|
Market Analysis |
US$ Million for Value |
|
Key Regions Covered |
|
|
Key Countries Covered |
|
|
Key Market Segments Covered |
|
|
Key Companies Profiled |
|
|
Report Coverage |
|
|
Customization & Pricing |
Available upon request |
By Product Type:
By Application:
By End-User:
By Region:
For report customisation and delivery information contact our sales representative.
The market is anticipated to grow at a CAGR of 4.7% during the projected period.
The functional electrical stimulation market was valued at US$615 million in 2023.
The US held the largest market share in 2023.
Some of the prominent players in the market are Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi S.A., and GlaxoSmithKline plc.
The wired segment is expected to grow at the fastest CAGR during the forecast period.
